Arcturus Therapeutics Holdings Inc. (ARCT) Stock Analysis & Investment Frameworks

Arcturus Therapeutics Holdings Inc. (ARCT) stock analysis on Invetso. Review Arcturus Therapeutics Holdings Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Arcturus Therapeutics Holdings Inc. Company Overview

Arcturus Therapeutics Holdings Inc. Key Financial Metrics

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.

Arcturus Therapeutics Holdings Inc. Investment Frameworks

Invetso analyzes Arcturus Therapeutics Holdings Inc. (ARCT) across the following frameworks:

Explore More ARCT Research